Genmab stock slides today as GMAB shelves acasunlimab; Merus takeout steps in focus
NEW YORK, December 31, 2025, 11:38 ET — Regular session Genmab A/S (GMAB) shares slid on Wednesday, down about 3.3% at $30.44 in New York trading, as investors weighed a late-stage pipeline cut and the closing steps of a major acquisition. The Nasdaq-listed ADR touched $30.36 after opening at $31.42. Genmab said on Dec. 29 it will discontinue further clinical…